Aspirin: A neuroprotective agent at high doses?

National Medical Journal of India

Volumn 11, Issue 1, 1998, Pages 14-17

  Gomes, Ivone ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

DOSE RESPONSE; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; HUMAN; NEUROPROTECTION; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; ASPIRIN; CALCIUM; CEREBROVASCULAR DISORDERS; CYCLOOXYGENASE INHIBITORS; GLUTAMATES; HUMANS; NEUROPROTECTIVE AGENTS; NF-KAPPA B;

EID: 0031949952     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Tymianski M, Tator CH. Normal and abnormal calcium homeostasis in neurons: A basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 1996;38:1176-95.
2. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci 1992;15:303-8.
3. Chard PS, Bleakman D, Christakos S, Fullmer CS, Miller RJ. Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 1993;472:341-57.
4. +2 pump in the plasma membrane. J Biol Chem 1992;267: 2115-18.
5. Nachshen DA, Sanchez-Armass S, Weinstein AM. The regulation of cytosolic calcium in rat brain synaptosomes by sodium dependent calcium efflux. J Physiol 1986;381:17-28.
6. Blaustein MP. Calcium transport and buffering in neurons. Trends Neurosci 1988; 11:438-43.
7. +2 exchanger. J Neurosci 1992; 12:430-9.
8. Abele AE, Scholz KP, Scholz WK, Miller RJ. Excitotoxicity induced by enhanced excitatory neurotransmission in cultured hippocampal pyramidal neurons. Neuron 1990;4:413-19.
9. Rosenberg PA, Aizenman E. Hundred-fold increase in neuronal vulnerability to glutamate toxicity in astrocyte-poor culture of rat cerebral cortex. Neurosci Letts 1989;103:162-8.
10. Rosenberg PA, Amin S, Leitner M. Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex dissociated cell culture. J Neurosci 1992; 12:56-61.
11. Seeburg PH. The molecular biology of mammalian glutamate receptor channels. Trends Pharmacol Sci 1993;14:297-302.
12. Schoepp DD, Conn PJ. Metabotrophic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 1993;14:13-19.
13. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanism of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 1993;13: 2651-61.
14. Schmidley JW. Free radicals in central nervous system ischemia. Stroke 1990;21: 1086-90.
15. Farooqui AA, Horrocks LA. Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders. Brain Res Rev 1991;16: 171-91.
16. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci 1990;10:1035-41.
17. Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci 1989,9: 1579-90.
18. Kirino T. Delayed neuronal death in gerbil hippocampus following ischemia. Brain Res 1982;239:57-69.
19. Tominaga T, Kure S, Yoshimoto T. Temporal profile of DNA degradation in injured rat brain. J Cereb Blood Flow Metab 1993;13:S460.
20. Faden AI, Salzman S. Pharmacological strategies in CNS trauma. Trends Pharmacol Sci 1992;13:29-35.
21. Fisher M, Grotta J. New uses for calcium channel blockers: Therapeutic implications. Drugs 1993;46:961-75.
22. +2 release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 1991;56:1075-8.
23. Mattson MP, Zhang Y, Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol 1993;121:1-13.
24. +2 dynamics after toxic doses of glutamate in cerebellar granule cells. Proc Natl Acad Sci USA 1990;87:8017-21.
25. +2 chelators. J Cereb Blood Flow Metab 1994;14:911-23.
26. Hall ED. Neuroprotective actions of glucocorticoid and nonglucocorticoid steroids in acute neuronal injury. Cell Mol Neurobiol 1993;13:415-32.
27. Muizelaar JP. Cerebral ischemia-reperfusion injury after severe head injury and its possible treatment with polyethylene glycol-superoxide dismutase. Ann Emerg Med 1993;22:1014-21.
28. Buisson A, Plotkine M, Boulu RG. The neuroprotcctive effect of a nitric oxide inhibitor in a rat model of focal cerebral ischemia. Br J Pharmacol 1992;106: 766-7.
29. Nishikawa T, Kirsch JR, Koehler RC, Bredt DS, Snyder SH, Traystman RJ. Effects of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal cerebral ischemia in cats. Stroke 1993;23:1717-24.
30. Roberts-Lewis JM, Marcy VR, Zhao Y, Vaught JL, Siman R, Lewis ME. Aurintricarboxylic acid protects hippocampal neurons from NMDA- and ischemia-induced toxicity in vivo. J Neurochem 1993;61:378-81.
31. Sila CA. Prophylaxis and treatment of stroke: The state of the art in 1993. Drugs 1993;45:329-37.
32. Insel PA. Analgesics-antipyretics and antiinflammatory agents and drugs employed in the treatment of gout. In: Molinoff PM, Ruddon RW (eds). Goodman and Gilman's The pharmacological basis of therapeutics. New York:McGraw-Hill International, 1995:617-57.
33. Aas AT, Tonnessen TI, Brun A, Salford LG. Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J Neuro-oncol 1995;24:171-80.
34. Weissmann G. Aspirin: After more than 200 years, the mechanisms by which this venerable drug and its relatives achieve their wide range of effects have yet to be fully elucidated. Sci Am 1991;264:58-64.
35. Jurivich DA, Sistonen L, Kroes RA, Morimoto RI. Effect of sodium salicylate on the human heat shock response. Science 1992;255:1243-5.
36. Malamy J, Carr JP, Klessig DF, Raskin I. Salicylic acid: A likely endogenous signal in the resistance response of tobacco to viral infection. Science 1990;250:1002-4.
37. Metraux JP, Signer H, Ryals J, Ward E, Wyss-Benz M, Gaudin J, et al. Increase in salicylic acid at the onset of systemic acquired resistance in cucumber. Science 1990;250:1004-6.
38. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-9.
39. Grilli M, Chiu JJ-S, Lenardo MJ. NF-kappa B and rel: Participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-62.
40. Muller S, Kammerbauer C, Simons U, Shibagaki N, Li LJ, Caughman SW, et al. Transcriptional regulation of intercellular adhesion molecule-1: PMA-induction is mediated by NF-kappa B. J Invest Dermatol 1995;104:970-5.
41. Neish AS, Williams AJ, Palmer HJ, Whitley M, Collins T. Functional analysis of the human vascular cell adhesion molecule-1 promoter. J Exp Med 1992;176: 15833-93.
42. Beg AA, Finco TS, Nantermet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to the phosphorylation and loss of I kappa B alpha: A mechanism for NF-kappa B activation. Mol Cell Biol 1993;13:3301-10.
43. Macilwain C. Aspirin on trial as HIV treatment. Nature 1993;364:369.
44. Grili M, Pizzi M, Merno M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 1996;274:1383-5.
45. Kaltschmidt C, Kaltschmidt B, Baeuerle PA. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc Natl Acad Sci USA 1995;92:9618-22.
46. Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA 1995;92: 9077-81.
47. Grilli F, Goffi F, Memo M, Spano PF. Interleukin-1 beta and glutamate activate the NF-kappa B/rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem 1996;271:15002-7.
48. Curran T, Franza BR Jr. Fos and Jun: The AP-1 connection. Cell 1988;55:395-7.
49. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979;103:359-62.
50. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992;59:1080-9.
51. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990;30:1-45.
52. Rao GHR, Gerrard JM, Eaton JW, White JG. The role of iron in prostaglandin synthesis: Ferrous iron mediated oxidation of arachidonic acid. Prostaglandins Med 1978;1:55-70.
53. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 1991;56: 978-82.
54. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem 1995;64:1645-54.
55. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: Implication for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1389-400.
56. Hastings TG. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 1995;64:919-25.
57. DiMonte DA, Chan P, Sandy MS. Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage. Ann Neurol 1992;32: S111-S15.